Ligand Pharma Director John Kozarich Sells 381 Shares in Quiet, Rule‑Based Move as Stock Nears 52‑Week High
Insightful analysis of Ligand Pharmaceuticals’ insider sales, showing steady divestiture, confidence in future prospects, and potential liquidity moves.
3 minutes to read